Efficacy | Eliquis

ADVANCE-2: A study of VTE prevention in patients undergoing elective TKR³

*Total VTE/all-cause death: composite of asymptomatic and symptomatic VTE, non-fatal PE and all-cause death.³

†Major VTE: composite of asymptomatic and symptomatic proximal DVT, non-fatal PE and Venous Thromboembolism-related death.³

Inclusion criteria:³

Patients were eligible for inclusion if they were scheduled to undergo unilateral elective total knee replacement or same-day bilateral knee replacement, including revision.

Key exclusion criteria:³ 

Key exclusion criteria included the following:

Active bleeding
Contraindication to anticoagulant prophylaxis
Need for ongoing anticoagulant or antiplatelet treatment
Uncontrolled hypertension
Active hepato-biliary disease
Impaired renal function
Thrombocytopenia
Anemia
Heparin allergy
Allergy to radiographic contrast dye
Other disorders preventing venography

Eliquis® demonstrated significant reductions in total Venous Thromboembolism/all- cause death and in major VTE vs. enoxaparin after knee replacement³

Adapted from Lassen MR, et al. Lancet. 2010.

‡Total Venous Thromboembolism/all-cause death: composite of asymptomatic and symptomatic Venous Thromboembolism, non-fatal PE, and all-cause death.³

§Major VTE: composite of asymptomatic and symptomatic proximal DVT, non-fatal PE, and Venous Thromboembolism-related death.³

In ADVANCE-2, a multicentre, randomised, double-blind, phase III study, patients undergoing elective unilateral or bilateral TKR were randomly allocated through an interactive central telephone system to receive oral apixaban 2.5 mg BID (n=1,528) or SC enoxaparin 40 mg once daily. Apixaban was started 12-24 hours after wound closure and enoxaparin 12 hours before surgery; both drugs were continued for 10-14 days, when bilateral ascending venography was scheduled. Primary outcome was the composite of asymptomatic and symptomatic DVT, non-fatal PE, and all-cause death during treatment.³

ADVANCE-2: Apixaban versus Enoxaparin for Thromboprophylaxis after Knee Replacement; BID: twice daily; DVT: deep-vein thrombosis; PE: pulmonary embolism; RRR: relative risk reduction; QD: once daily; SC: subcutaneous; TKR: total knee replacement; VTE: venous thromboembolism.

References: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. 3. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet. 2010;375(9717):807-815.

Explore more

SPAF Dosing

Learn more

Click here for Eliquis® 2.5mg Prescribing Information Click here for Eliquis® 5mg Prescribing Information	HF0098OA456/122022 Invalidation Date : 21/08/2024

Quick Links

SPAF Guideline recommendations

Learn more

VTE treatment Dosing

Learn more

ADVANCE-3: A study of Venous Thromboembolism prevention in patients undergoing elective THR³

*Total Venous Thromboembolism/all-cause death: composite of asymptomatic and symptomatic Venous Thromboembolism, non-fatal PE and all-cause death.³

†Major VTE: composite of asymptomatic and symptomatic proximal DVT, non-fatal PE and Venous Thromboembolism-related death.³

Inclusion criteria:³

Patients were eligible for inclusion if they were scheduled to undergo elective THR or revision of a previously inserted hip prosthesis.

Key exclusion criteria: ³
Key exclusion criteria included the following:

Active bleeding
Contraindication to anticoagulant prophylaxis
Need for ongoing anticoagulant or antiplatelet treatment
Uncontrolled hypertension
Active hepato-biliary disease
Impaired renal function
Thrombocytopenia
Anemia
Heparin allergy
Allergy to radiographic contrast dye
Other disorders preventing venography

Eliquis® demonstrated significant reductions in total Venous Thromboembolism/all- cause death and in major Venous Thromboembolism vs. enoxaparin after hip replacement³

Adapted from Lassen MR, et al. Lancet. 2010.

In this double-blind, double-dummy study, we randomly assigned 5,407 patients undergoing THR to receive apixaban at a dose of 2.5 mg orally BID or enoxaparin at a dose of 40 mg subcutaneously every 24 hours. Apixaban therapy was initiated 12 to 24 hours after closure of the surgical wound; enoxaparin therapy was initiated 12 hours before surgery. Prophylaxis was continued for 35 days after surgery, followed by bilateral venographic studies. The primary efficacy outcome was the composite of asymptomatic or symptomatic DVT, non-fatal PE, or death from any cause during the treatment period. Patients were followed for an additional 60 days after the last intended dose of study medication.³

ADVANCE-3: Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement; BID: twice daily; DVT: deep-vein thrombosis; PE: pulmonary embolism; RRR: relative risk reduction; QD: once daily; SC: subcutaneous; THR: total hip replacement; VTE: venous thromboembolism

Reference: 1. Eliquis 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. 3. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487-2498.

Explore more

VTE treatment Dosing

Learn more

Click here for Eliquis® 2.5mg Prescribing Information Click here for Eliquis® 5mg Prescribing Information	HF0098OA456/122022 Invalidation Date : 21/08/2024

Quick Links

SPAF Aristophanes

Learn more

SPAF Dosing

Learn more